Status:

RECRUITING

Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)

Lead Sponsor:

Sanofi

Conditions:

Polyneuropathy, Inflammatory Demyelinating, Chronic

Eligibility:

All Genders

18+ years

Brief Summary

This study is an observational, ambispective, descriptive, non-interventional study of people with a chronic inflammatory demyelinating polyneuropathy/polyradiculoneuropathy (CIDP) diagnosis in the Un...

Eligibility Criteria

Inclusion

  • Participants are eligible to be included in the study only if all of the following criteria apply:
  • Neurologist-confirmed diagnosis of CIDP found in the medical record, with the last neurologist visit prior to enrollment containing no information that suggests this diagnosis was reversed
  • Active use of at least one of the following CIDP treatments for three months or longer, with no evidence of discontinuation of this therapy as of the last neurologist visit prior to enrollment
  • immunoglobulin
  • corticosteroids, with the exception of prednisone (or equivalent) monotherapy at 10mg or less per day
  • plasma exchange
  • efgartigimod alfa
  • azathioprine
  • mycophenolate mofetil
  • cyclosporine
  • rituximab
  • methotrexate
  • Signed informed consent
  • Residual impairment, disability, or neurological deficits at enrollment, as defined by a raw I-RODS score of 44 or below

Exclusion

  • Participants are excluded from the study if any of the following criteria apply:
  • Evidence of participation in any interventional clinical trial with an investigational drug at the time of enrollment
  • Hyperreflexia (increased reflexes) recorded in the medical record during a neurological exam the year before enrollment and after CIDP diagnosis
  • Aged under 18 at the time of enrollment
  • The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Key Trial Info

Start Date :

April 11 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

May 17 2027

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT06968975

Start Date

April 11 2025

End Date

May 17 2027

Last Update

June 29 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Investigational Site

Swiftwater, Pennsylvania, United States, 18370-0187